Cardinal Health Inc (CAH-N)

9% forecast growth rate, trading ~14x forward PE. Not a bad valuation to growth rate. Great chart of higher highs and higher lows. Outpacing S&P since late 2021. Pricing power and favourable demographics. Yield is 1.6%.

3rd largest pharmacy distributor in the USA. Good job at new products and pricing strategy. Has recently streamlined operations. However, stock price fully valued. Would recommend buying on weakness (below $95/share). 

Healthcare space provides nice combination of growth with stability, in case we get into latter stage of economic cycle. 

Likes, and owns. As people age, volume of drugs required can only increase, benefiting a name like this.

Scores 4/10 on value, 3/10 on fundamentals. Try to avoid. If you're in it and looking for an exit, now's not a bad time because it's had a pop YTD. Only about 4% more upside to analysts' price targets.

She prefers larger, less volatile companies that are a bit more secure. Try UNH or big US pharmaceuticals.

Last week, they reported a top and bottom line beat and raised guidance. Q4 revenue grew 12% YOY

XLV gives you a basket of names, with some winners and some losers. LLY is the top holding, that's a winner. Also holds JNJ and PFE, which haven't done particularly well. 

He owns NVO, MCK and CAH. He likes those companies where the only serious competition comes from 1 or 2 others, as they can control pricing power. Diabetes and weight loss are definite growth areas. See his Top Picks.

In pharma space, prefers growthy areas such as distributors like CAH and MCK.

Healthcare strong, but stock performance mediocre. Will host CEO to get more answers. 

Recently sold at slight loss, EPS won't have the growth trajectory he thought. Announcement out of left field that they lost a contract and revenue would decline substantially. Reasonably stable business. Over time, will probably be an OK holding. But now market won't have the same confidence in management to execute, stock will be hobbled. He'd look again on further decline.

Does not own shares in business. Healthcare sector has tailwinds, but unsure on direction of this particular business. Expecting growth in pharma portion of business. Overall, healthcare has strong fundamentals. 

Third largest pharma distributor in USA. Very high performing company. Stock price and margins improving. Stock is fully valued at current price, but is watching closely. Would buy on weakness. 

It is a great business and he likes the business model. The tailwind is volume since it has picked up especially with the weight loss drugs.

Distributes pharma and medical products. Largest customer is CVS. Operates in a triopoly, controlling 90% of the US wholesale industry. Pricing power leads to predictable cashflow. Aging population, weight-loss drugs, diabetes treatments will result in higher spending and volume. Shares trending steadily higher, good technical strength. 15% earnings growth going forward. Yield is 1.9%.

They just reported a revenue and earnings beat, and raised their full-year forecast, but missed operating profit and lowered their full-year forecast for the smaller medical segment. Shares tumbled yesterday and today but is still close to its all-time high. Doesn't understand the sell-off.